Insmed Incorporated (NASDAQ:INSM) Receives Consensus Rating of “Buy” from Brokerages

Insmed Incorporated (NASDAQ:INSM) has been given an average recommendation of “Buy” by the sixteen ratings firms that are covering the firm, MarketBeat.com reports. Sixteen research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $83.67.

A number of research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. TD Cowen increased their price objective on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Stifel Nicolaus increased their price objective on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, UBS Group increased their price objective on shares of Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Insider Buying and Selling

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. The trade was a 27.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently made changes to their positions in INSM. Darwin Global Management Ltd. acquired a new stake in shares of Insmed in the 2nd quarter valued at $237,076,000. Capital International Investors bought a new stake in Insmed during the 1st quarter worth about $43,973,000. Clearbridge Investments LLC bought a new stake in shares of Insmed in the 1st quarter valued at about $25,242,000. Vestal Point Capital LP increased its stake in Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares in the last quarter. Finally, Fiera Capital Corp bought a new stake in Insmed during the 2nd quarter worth approximately $40,570,000.

Insmed Stock Down 0.9 %

NASDAQ INSM opened at $73.15 on Monday. Insmed has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company’s fifty day moving average price is $72.04 and its two-hundred day moving average price is $66.31.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter last year, the business earned ($1.10) EPS. Insmed’s revenue was up 18.1% compared to the same quarter last year. Equities analysts anticipate that Insmed will post -5.42 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.